Sector News

Categories

Borderless Insights

Image
Ditch Your CV Biases: Finding Your Next Leader Demands a Storyteller’s Curiosity
Image
Career 2.0: Mid-Career Transition for the Over-50 Executive
Image
How can we really achieve gender equity in the C-Suite?

UCB, Advent, Avista End Acquisition Agreement

December 17, 2014
Life sciences
Belgian pharmaceutical company UCB SA (UCB.BT), Advent International and Avista Capital Partners ended an acquisition agreement that would have seen Advent and Avista buy UCB’s U.S.-based speciality generics subsidiary for $ 1.5 billion, the company said in a press release.
 
UCB said it still plans to divest the generics unit, Kremers Urban Pharmaceutical Inc. It said the decision to terminate the acquisition agreement, which was signed last month, was a result of an “unexpected conflict” between the timing of the deal and a regulatory process launched in the U.S.
 
On Nov. 14, Kremers Urban said it had been informed by the U.S. Food and Drug Administration that the agency wanted an additional study on one of the company’s products–the methylphenidate hydrochloride extended-release (ER) tablet.
 
“While we are working on clarifying the situation around methylphenidate ER we will continue the divestiture process for Kremers Urban,” said Detlef Thielgen, Chief Financial Officer of UCB.
 
UCB said Tuesday’s announcement doesn’t impact the company’s most recent 2014 financial outlook, with the firm contining to expect total revenue of EUR3.15 billion-EUR3.25 billion ($3.94 billion-$4.07 billion) and underlying profits of EUR590 million to EUR620 million.
 
UCB’s shares closed 0.6% higher at EUR64.06.
 
By Laurence Norman
 
Source: Dow Jones Business News

comments closed

Related News

September 22, 2023

Novo Holdings acquires biopharma company Paratek for $462m

Life sciences

Novo Holdings has concluded the acquisition of all outstanding shares of commercial-stage biopharmaceutical company Paratek Pharmaceuticals for nearly $462m (€433.67m) to bolster its antimicrobial resistance (AMR) expertise. Paratek develops and commercialises new treatments for life-threatening ailments. Its speciality pharmaceutical platform aids in developing new therapeutics.

Read more
September 22, 2023

Glenmark Pharma to divest 75% stake in life sciences unit for $680m

Life sciences

Glenmark Pharmaceuticals has signed a definitive agreement for the divestiture of a 75% stake in its division, Glenmark Life Sciences (GLS), to Indian company Nirma in a deal valued at Rs56.51bn ($679.85m). Glenmark Life Sciences focuses on producing active pharmaceutical ingredients (API).

Read more
September 22, 2023

Lonza-CEO Ruffieux to leave Swiss CDMO

Life sciences

Pierre-Alain Ruffieux, CEO of Lonza, will leave the Basel-based company at the end of September. According to the Swiss Contract Development and Manufacturing Organization (CDMO), the separation is by mutual agreement.

Read more
More news

How can we help you?

We're easy to reach